Yazdi Amirhossein, Shirmohammadi Kimia, Parvaneh Erfan, Entezari-Maleki Taher, Hosseini Seyed Kianoosh, Ranjbar Akram, Mehrpooya Maryam
Department of Cardiology, School of Medicine, Clinical Research Development Unit of Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
J Cardiovasc Thorac Res. 2023;15(4):250-261. doi: 10.34172/jcvtr.2023.31817. Epub 2023 Dec 30.
It is well-established that oxidative stress is deeply involved in myocardial ischemia-reperfusion injury. Considering the potent antioxidant properties of coenzyme Q10 (CoQ10), we aimed to assess whether CoQ10 supplementation could exert beneficial effects on plasma levels of oxidative stress biomarkers in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPIC).
Seventy patients with the first attack of STEMI, eligible for PPCI were randomly assigned to receive either standard treatments plus CoQ10 (400 mg before PPCI and 200 mg twice daily for three days after PPCI) or standard treatments plus placebo. Plasma levels of oxidative stress biomarkers, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), total antioxidant capacity (TAC), and malondialdehyde (MDA) were measured at 6, 24, and 72 hours after completion of PPCI.
The changes in plasma levels of the studied biomarkers at 6 and 24 hours after PPCI were similar in the both groups ( values>0.05). This is while at 72 hours, the CoQ10- treated group exhibited significantly higher plasma levels of SOD ( value<0.001), CAT ( value=0.001), and TAC ( value<0.001), along with a lower plasma level of MDA ( value=0.002) compared to the placebo-treated group. The plasma activity of GPX showed no significant difference between the groups at all the study time points ( values>0.05).
This study showed that CoQ10 has the potential to modulate the balance between antioxidant and oxidant biomarkers after reperfusion therapy. Our results suggest that CoQ10, through its antioxidant capacity, may help reduce the reperfusion injury in ischemic myocardium.
氧化应激与心肌缺血再灌注损伤密切相关，这一点已得到充分证实。鉴于辅酶Q10（CoQ10）具有强大的抗氧化特性，我们旨在评估补充CoQ10是否能对接受直接经皮冠状动脉介入治疗（PPIC）的ST段抬高型心肌梗死（STEMI）患者血浆氧化应激生物标志物水平产生有益影响。
70例首次发作且符合PPIC条件的STEMI患者被随机分为两组，一组接受标准治疗加CoQ10（PPIC前400mg，PPIC后三天每天两次，每次200mg），另一组接受标准治疗加安慰剂。在PPIC完成后6、24和72小时测量血浆氧化应激生物标志物水平，包括超氧化物歧化酶（SOD）、过氧化氢酶（CAT）、谷胱甘肽过氧化物酶（GPx）、总抗氧化能力（TAC）和丙二醛（MDA）。
PPIC后6和24小时两组研究生物标志物的血浆水平变化相似（P值>0.05）。而在72小时时，与安慰剂治疗组相比，CoQ10治疗组的SOD血浆水平显著更高（P值<0.001）、CAT血浆水平显著更高（P值=0.001）、TAC血浆水平显著更高（P值<0.001），同时MDA血浆水平更低（P值=0.002）。在所有研究时间点，两组间GPX的血浆活性均无显著差异（P值>0.05）。
本研究表明，CoQ10有可能调节再灌注治疗后抗氧化和氧化生物标志物之间的平衡。我们的结果表明，CoQ10通过其抗氧化能力，可能有助于减少缺血心肌的再灌注损伤。
